• Je něco špatně v tomto záznamu ?

HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study

P. Dundr, M. Bártů, J. Hojný, R. Michálková, N. Hájková, I. Stružinská, E. Krkavcová, L. Hadravský, L. Kleissnerová, J. Kopejsková, BQ. Hiep, K. Němejcová, R. Jakša, O. Čapoun, J. Řezáč, K. Jirsová, V. Franková

. 2020 ; 10 (1) : 14365. [pub] 20200901

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012232

Grantová podpora
NV17-28404A MZ0 CEP - Centrální evidence projektů

Hepatocyte nuclear factor 1 beta (HNF1B) is a tissue specific transcription factor, which seems to play an important role in the carcinogenesis of several tumors. In our study we focused on analyzing HNF1B in prostate carcinoma (PC) and adenomyomatous hyperplasia (AH), as well as its possible relation to the upstream gene EZH2 and downstream gene ECI2. The results of our study showed that on an immunohistochemical level, the expression of HNF1B was low in PC, did not differ between PC and AH, and did not correlate with any clinical outcomes. In PC, mutations of HNF1B gene were rare, but the methylation of its promotor was a common finding and was positively correlated with Gleason score and stage. The relationship between HNF1B and EZH2/ECI2 was equivocal, but EZH2 and ECI2 were positively correlated on both mRNA and protein level. The expression of EZH2 was associated with poor prognosis. ECI2 did not correlate with any clinical outcomes. Our results support the oncosuppressive role of HNF1B in PC, which may be silenced by promotor methylation and other mechanisms, but not by gene mutation. The high expression of EZH2 (especially) and ECI2 in PC seems to be a potential therapeutic target.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012232
003      
CZ-PrNML
005      
20210507104344.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-020-71427-7 $2 doi
035    __
$a (PubMed)32873863
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic. pavel.dundr@vfn.cz
245    10
$a HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study / $c P. Dundr, M. Bártů, J. Hojný, R. Michálková, N. Hájková, I. Stružinská, E. Krkavcová, L. Hadravský, L. Kleissnerová, J. Kopejsková, BQ. Hiep, K. Němejcová, R. Jakša, O. Čapoun, J. Řezáč, K. Jirsová, V. Franková
520    9_
$a Hepatocyte nuclear factor 1 beta (HNF1B) is a tissue specific transcription factor, which seems to play an important role in the carcinogenesis of several tumors. In our study we focused on analyzing HNF1B in prostate carcinoma (PC) and adenomyomatous hyperplasia (AH), as well as its possible relation to the upstream gene EZH2 and downstream gene ECI2. The results of our study showed that on an immunohistochemical level, the expression of HNF1B was low in PC, did not differ between PC and AH, and did not correlate with any clinical outcomes. In PC, mutations of HNF1B gene were rare, but the methylation of its promotor was a common finding and was positively correlated with Gleason score and stage. The relationship between HNF1B and EZH2/ECI2 was equivocal, but EZH2 and ECI2 were positively correlated on both mRNA and protein level. The expression of EZH2 was associated with poor prognosis. ECI2 did not correlate with any clinical outcomes. Our results support the oncosuppressive role of HNF1B in PC, which may be silenced by promotor methylation and other mechanisms, but not by gene mutation. The high expression of EZH2 (especially) and ECI2 in PC seems to be a potential therapeutic target.
650    _2
$a senioři $7 D000368
650    _2
$a kohortové studie $7 D015331
650    _2
$a metylace DNA $7 D019175
650    _2
$a enoyl-CoA-izomeráza $x genetika $x metabolismus $7 D064006
650    _2
$a EZH2 protein $x genetika $x metabolismus $7 D000071221
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a hepatocytární jaderný faktor 1-beta $x genetika $x metabolismus $7 D051539
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a prognóza $7 D011379
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a prostata $x patologie $7 D011467
650    _2
$a hyperplazie prostaty $x genetika $x metabolismus $x patologie $7 D011470
650    _2
$a nádory prostaty $x genetika $x metabolismus $x patologie $7 D011471
650    _2
$a messenger RNA $x genetika $7 D012333
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Hojný, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Michálková, Romana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Hájková, Nikola $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Stružinská, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Krkavcová, Eva $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Hadravský, Ladislav $u Institute of Pathology, First Faculty of Medicine, Charles University, Prague 2, Czech Republic
700    1_
$a Kleissnerová, Lenka $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Kopejsková, Jana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Hiep, Bui Quang $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Jakša, Radek $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic
700    1_
$a Čapoun, Otakar $u Department of Urology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, Czech Republic
700    1_
$a Řezáč, Jakub $u Department of Urology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, Czech Republic
700    1_
$a Jirsová, Kateřina $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, Czech Republic
700    1_
$a Franková, Věra $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, Czech Republic
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 14365
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32873863 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507104342 $b ABA008
999    __
$a ok $b bmc $g 1650576 $s 1132611
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 1 $d 14365 $e 20200901 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a NV17-28404A $p MZ0
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

    Možnosti archivace